Microcide Pharmaceuticals (MCDE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Microcide Pharmaceuticals (MCDE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Silverman who wrote (78)	6/2/1997 6:06:00 PM
From: Czechsinthemail	of 186

I agree on the assessment of CBST and MCDE. MCDE appears to be the more undervalued of the two, and I hope management isn't too proud to spotlight their company and toot their horn a bit. Besides being the way virtually everyone in and around the company makes money, having a strong stock price performance is a big advantage in securing employees and raising capital. Regarding their antifungal work, how much synergy, if any, are they likely to have between their antibiotic and antifungal research programs? I don't immediately see much, which raises the question of focused vs. broad research programs. Are they likely to be spreading themselves thin by pursuing both areas and/or likely to be overextended financially down the road as they face expanding funding requirements for both areas of R&D? Do they have the same compelling need in terms of drug-resistant fungi that is presented by drug-resistant bacteria? Does anyone know how big their antifungal effort is at this point or is it largely something for the future? Baird

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next